|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||0.105 - 0.106|
|52 Week Range||0.100 - 1.490|
|Beta (3Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
TearLab Corporation (TEAR) (“TearLab” or the “Company”), today announced that the U.S. Food and Drug Administration (FDA) has determined that the TearLab Discovery™ MMP-9 test, has not met the criteria for substantial equivalence based upon data and information submitted by TearLab in its 510(k) submission. “We understand the FDA’s position and are encouraged by the clear guidance they have provided. The TearLab Discovery platform is designed to enable eye care professionals to assess multiple biomarkers in human tears with nanoliter volume tear collection.
On a per-share basis, the San Diego-based company said it had a loss of 6 cents. The ophthalmic device company posted revenue of $6.4 million in the period. In the final minutes of trading on Thursday, ...
SAN DIEGO, Aug. 09, 2018-- TearLab Corporation today reported its consolidated financial results for the second quarter ended June 30, 2018. All dollar amounts are expressed in U.S. currency and results ...
On a per-share basis, the San Diego-based company said it had a loss of 9 cents. The ophthalmic device company posted revenue of $6.4 million in the period. The company's shares closed at 24 cents. A year ...
On a per-share basis, the San Diego-based company said it had a loss of 63 cents. Losses, adjusted for asset impairment costs, came to 55 cents per share. The ophthalmic device company posted revenue of ...
NEW YORK, NY / ACCESSWIRE / February 23, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...
Categories: Yahoo FinanceGet free summary analysis TearLab Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of TearLab Corp. – STAAR Surgical Company, Atrion Corporation and Vuzix Corporation (STAA-US, ATRI-US and VUZI-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 6.52 ... Read more (Read more...)
The San Diego-based company said it had a loss of 67 cents per share. The ophthalmic device company posted revenue of $6.5 million in the period. In the final minutes of trading on Monday, the company's ...
In this analysis, my focus will be on developing a perspective on TearLab Corporation’s (NASDAQ:TEAR) latest ownership structure, a less discussed, but important factor. The impact of a company’s ownershipRead More...